Dr. Darshan Dalal is Chief Medical Officer at Actithera, where he leads the company’s clinical strategy and development organization as Actithera advances its next-generation radioligand therapy pipeline. He brings more than 15 years of global leadership experience across oncology, hematology, and radiopharmaceutical development, with a track record of advancing over 10 radioligands from preclinical research through Phase III development. Prior to joining Actithera, Darshan held radioligand leadership roles at AstraZeneca and Novartis, where he led global programs across multiple solid tumor indications including key contributions to the development of Pluvicto. He earned his MD, PhD, and MPH degrees from University of Bombay and Johns Hopkins University. His extensive expertise in radioligand therapy development continues to support Actithera’s mission to build differentiated precision oncology therapeutics.